The American Journal of Managed Care: Focus Turns to Unmet Needs in ITP, Related Autoimmune Diseases After Rilzabrutinib Approval: David Kuter, MD, DPhil Focus Turns to Unmet Needs in ITP, Related Autoimmune Diseases After Rilzabrutinib Approval: David Kuter, MD, DPhil A 47-year-old woman in Germany had spent more than a decade battling three severe autoimmune diseases at once: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid ... The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy. I think the major challenges in ITP are several.

Understanding the Context

One, and I think the [rilzabrutinib] ... Fierce Biotech: In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, providing further proof of the modality’s promise in the disease area as a ... In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient FierceBiotech: ASH: Sanofi's BTK inhibitor raises platelet levels in 23% of ITP patients in phase 3